If you want to understand the weirdest pattern haunting Silicon Valley right now, start with one idea: some unicorns should have been killed off by the market years ago, but they are still alive, mostly through accounting and expectations. The Economist frames the problem bluntly: years of frothy valuations have created a nightmare. These firms get to stay classified as valuable, even as underlying fundamentals weaken, which turns the ecosystem into something closer to a slow-motion reckoning than a clean market reset.

The “zombie” label matters because it is about incentives. In a valuation boom, it is easy for everyone involved to treat high prices as proof of future success. But high prices are also just numbers at a point in time, and they can become a crutch. When a startup’s valuation is repeatedly supported by fresh capital and the market’s willingness to pay up, it can remain above the magic line that keeps it attractive to investors, employees, and strategic partners. The Economist’s core point is that this dynamic can keep weak companies standing after the moment they should have failed, which is what makes them zombies.

To see why this becomes a nightmare for decision-makers, zoom out to how capital markets in tech typically work. In early-stage investing, valuations often move faster than revenues, and the story about future dominance can dominate the spreadsheet. That can be rational if growth is truly accelerating. But when froth lasts longer than fundamentals, valuation becomes self-reinforcing: existing shareholders can raise money at high prices, new money comes in because the headline valuation is visible, and internal teams can plan around inflated expectations.

Now add board behavior. Boards are supposed to be reality checks, but they also have to navigate investor pressure and career risk. If the board’s stakeholders are anchored to a valuation narrative, they may hesitate to force difficult decisions like down rounds, restructurings, or strategic pivots that could reduce status. Even if executives know the business is not performing as implied, the boardroom calculus can shift toward “keep it alive long enough” because time buys options. Options might mean a product breakthrough, a new customer wave, or an investor window that reopens. In a frothy era, those hopes are easier to underwrite.

Regulation and disclosure dynamics can also shape what “zombie” looks like in practice. Public markets and disclosure regimes tend to shine a light differently than private ones, but private markets still operate under the reality of scrutiny, investor due diligence, and periodic repricing. Once the environment shifts, the valuations that looked stable can unwind quickly, because the market is no longer willing to pay for the story without matching evidence. That is the trap: zombies are not just weak companies, they are companies whose survival depends on continued tolerance for inflated expectations.

The second-order implication is that zombies distort competition. When a firm survives longer than it should, it can keep spending in ways a healthier company would not. It can bid for talent, negotiate partnerships, and sustain growth efforts even if it is not on a credible path to profitability. That changes the competitive baseline for everyone else. Strong companies may find themselves competing against balance sheets that can keep losing longer than they should, not because they have superior unit economics, but because they have access to valuation momentum.

There is also a portfolio effect for investors and lenders. If a meaningful chunk of capital is locked in firms that are not truly compounding value, returns become harder to achieve across the board. The “zombie” problem means the market has to work through misallocated dollars before it can reward the next wave of genuinely high-performing companies. That is why the Economist’s framing of years of frothy valuations as a nightmare lands: the damage does not vanish when the boom cools. It persists until the ecosystem re-prices risk and stops treating inflated valuations as progress.

For peers who sit in board decks and investment committees, the stakes are immediate. If valuations can stay elevated while the business degrades, then the most important job is not just picking winners, it is setting guardrails that detect reality early. In other words, the market cannot afford a world where the definition of “valuable” is delayed by accounting optics. Zombies are the sign that the system waited too long to correct itself, and when corrections come, they tend to come fast.